<p>箭头制药公司（NASDAQ:ARWR - 获取免费报告）在周四创下了新的 52 周高点。该公司的交易最高达到 31.14 美元，最后交易价格为 30.82 美元，成交量为 610,791 股。该股票之前的收盘价为 29.13 美元。</p>
<h2>华尔街分析师观点</h2>
<ul>
<li>想要在生物技术领域获得多元化的上涨潜力？查看 LABU</li>
</ul>
<p>一些研究分析师最近对 ARWR 股票进行了评估。华尔街 Zen 在 7 月 18 日的报告中将箭头制药的评级从 “买入” 下调至 “持有”。加拿大皇家银行在 8 月 8 日的报告中将箭头制药的目标价格从 40.00 美元下调至 38.00 美元，并对该股票设定了 “跑赢大盘” 的评级。B. Riley 在 8 月 11 日的报告中将箭头制药的评级上调至 “强力买入”。Chardan Capital 在 8 月 11 日的研究报告中重申了 “买入” 评级，并对箭头制药的股票设定了 60.00 美元的价格目标。最后，HC Wainwright 在 9 月 2 日的研究报告中重申了 “买入” 评级，并对箭头制药的股票设定了 80.00 美元的价格目标。两位分析师给予该股票 “强力买入” 评级，四位分析师给予 “买入” 评级，两位分析师给予 “持有” 评级。根据 MarketBeat 的数据，该股票目前的平均评级为 “买入”，平均目标价格为 43.14 美元。</p>
<p><strong>查看我们对 ARWR 的最新分析</strong></p>
<h2>箭头制药股票表现</h2>
<p>该公司的市值为 43.1 亿美元，市盈率为-24.33，贝塔值为 1.00。该公司的 50 日移动平均价格为 20.67 美元，200 日移动平均价格为 16.76 美元。该公司的债务与股本比率为 0.39，速动比率为 4.87，流动比率为 4.87。</p>
<p>箭头制药（NASDAQ:ARWR - 获取免费报告）最近于 8 月 7 日发布了季度财报。该生物技术公司报告本季度每股收益为（1.26 美元），低于市场共识预期的（0.94 美元）32 美分。该公司在本季度的收入为 2777 万美元，而市场共识预期为 2901 万美元。在去年同期，该公司每股收益为（1.38 美元）。研究分析师平均预计箭头制药公司在本财年将发布每股收益为-2.42 美元。</p>
<h2>箭头制药的内部活动</h2>
<p>在其他消息中，内部人士詹姆斯·C·汉密尔顿在 9 月 12 日的交易中出售了 15,000 股公司的股票。该股票以平均价格 30.00 美元出售，总价值为 450,000.00 美元。交易后，内部人士直接持有 232,122 股公司的股票，价值 6,963,660 美元。此次交易使其持股减少了 6.07%。该出售在与证券交易委员会的法律文件中披露，相关信息可通过 SEC 网站获取。在过去 90 天内，内部人士出售了价值 1,025,000 美元的 40,000 股公司股票。4.30% 的股票由内部人士持有。</p>
<h2>机构资金流入和流出</h2>
<p>几家机构投资者和对冲基金最近调整了对该公司的持股。交易所交易概念公司在第一季度将其在箭头制药的持股增加了 31.8%。交易所交易概念公司目前持有 49,247 股生物技术公司的股票，价值 627,000 美元，此前在上个季度购买了 11,879 股。汇丰控股在第一季度获得了箭头制药的新头寸，价值 173,000 美元。GAMMA 投资公司在第一季度将其在箭头制药的持股增加了 297.6%。GAMMA 投资公司目前持有 2,175 股生物技术公司的股票，价值 28,000 美元，此前在上个季度购买了 1,628 股。纽约州教师退休系统在第一季度将其在箭头制药的持股增加了 6.9%。纽约州教师退休系统目前持有 148,376 股生物技术公司的股票，价值 1,890,000 美元，此前在上个季度购买了 9,593 股。最后，Principal Financial Group Inc.在第一季度将其在箭头制药的持股增加了 117.8%。Principal Financial Group Inc.目前持有 629,075 股生物技术公司的股票，价值 8,014,000 美元，此前在上个季度购买了 340,191 股。62.61% 的股票由机构投资者和对冲基金持有。</p>
<h2>箭头制药公司简介</h2>
<p>（获取免费报告）</p>
<p>箭头制药公司在美国开发用于治疗难治性疾病的药物。该公司的产品管线包括 Plozasiran，目前处于 2b 期和一项 3 期临床试验中，用于治疗高甘油三酯血症、混合性血脂异常和乳糜微粒血症；Zodasiran 目前处于 2b 期临床试验中，用于治疗血脂异常和高甘油三酯血症；ARO-PNPLA3，目前处于 1 期临床试验中，用于治疗非酒精性脂肪性肝炎患者；ARO-RAGE，目前处于 1/2a 期临床试验中，用于治疗炎症性肺部疾病；以及 ARO-MUC5AC，目前处于 1/2a 期临床试验中，用于治疗粘液阻塞性肺病。</p>
<h2>精选故事</h2>
<ul>
<li>我们更看好的五只股票比箭头制药更好</li>
<li>如何选择顶级评级股票</li>
<li>美联储降息：现在 S&amp;P 500 和股市该怎么办？</li>
<li>什么是 S&amp;P 500，它与其他指数有何不同</li>
<li>Bloom Energy 因 AI 电力需求和分析师升级而蓬勃发展</li>
<li>增长投资：您应该在 2022 年采用这种投资策略吗？</li>
<li>新催化剂为英特尔股票带来积极压力</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将有关此故事的任何问题或意见发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在箭头制药吗？</h2>
<p>在考虑箭头制药之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前立即购买……而箭头制药并不在名单上。</p>
<p>虽然箭头制药目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

箭头制药

<p>箭头制药 (NASDAQ:ARWR) 达到了新的 52 周高点 31.14 美元，收盘价为 30.82 美元，交易量为 610,791 股。分析师的评级各不相同，其中有两项强烈买入、四项买入和两项持有。该公司报告的季度每股亏损为 1.26 美元，未能达到预期，收入为 2777 万美元。内部人士詹姆斯·C·汉密尔顿出售了 15,000 股，减少了其持股比例。机构投资者持有 62.61% 的股份，反映出对这家生物技术公司的显著兴趣</p>

<p>Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Get Free Report) hit a new 52-week high on Thursday . The company traded as high as $31.14 and last traded at $30.82, with a volume of 610791 shares trading hands. The stock had previously closed at $29.13.</p>
<div class="lb-trans"><p>箭头制药公司（NASDAQ:ARWR - 获取免费报告）在周四创下了新的 52 周高点。该公司的交易最高达到 31.14 美元，最后交易价格为 30.82 美元，成交量为 610,791 股。该股票之前的收盘价为 29.13 美元。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师观点</h2>
</div><ul>
<li>Want Diversified Upside in Biotechnology? Check out LABU</li>
</ul>
<div class="lb-trans"><ul>
<li>想要在生物技术领域获得多元化的上涨潜力？查看 LABU</li>
</ul>
</div><p>A number of research analysts have recently weighed in on ARWR shares. Wall Street Zen downgraded Arrowhead Pharmaceuticals from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a report on Friday, July 18th. Royal Bank Of Canada lowered their price target on Arrowhead Pharmaceuticals from $40.00 to $38.00 and set an &#34;outperform&#34; rating on the stock in a report on Friday, August 8th. B. Riley upgraded Arrowhead Pharmaceuticals to a &#34;strong-buy&#34; rating in a report on Monday, August 11th. Chardan Capital reissued a &#34;buy&#34; rating and set a $60.00 price objective on shares of Arrowhead Pharmaceuticals in a research report on Monday, August 11th. Finally, HC Wainwright reissued a &#34;buy&#34; rating and set a $80.00 price objective on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, September 2nd. Two analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating and two have given a Hold rating to the company. According to MarketBeat, the stock presently has an average rating of &#34;Buy&#34; and an average price target of $43.14.</p>
<div class="lb-trans"><p>一些研究分析师最近对 ARWR 股票进行了评估。华尔街 Zen 在 7 月 18 日的报告中将箭头制药的评级从 “买入” 下调至 “持有”。加拿大皇家银行在 8 月 8 日的报告中将箭头制药的目标价格从 40.00 美元下调至 38.00 美元，并对该股票设定了 “跑赢大盘” 的评级。B. Riley 在 8 月 11 日的报告中将箭头制药的评级上调至 “强力买入”。Chardan Capital 在 8 月 11 日的研究报告中重申了 “买入” 评级，并对箭头制药的股票设定了 60.00 美元的价格目标。最后，HC Wainwright 在 9 月 2 日的研究报告中重申了 “买入” 评级，并对箭头制药的股票设定了 80.00 美元的价格目标。两位分析师给予该股票 “强力买入” 评级，四位分析师给予 “买入” 评级，两位分析师给予 “持有” 评级。根据 MarketBeat 的数据，该股票目前的平均评级为 “买入”，平均目标价格为 43.14 美元。</p>
</div><p><strong>View Our Latest Analysis on ARWR</strong></p>
<div class="lb-trans"><p><strong>查看我们对 ARWR 的最新分析</strong></p>
</div><h2>Arrowhead Pharmaceuticals Stock Performance</h2>
<div class="lb-trans"><h2>箭头制药股票表现</h2>
</div><p>The company has a market capitalization of $4.31 billion, a P/E ratio of -24.33 and a beta of 1.00. The firm has a 50 day moving average price of $20.67 and a two-hundred day moving average price of $16.76. The company has a debt-to-equity ratio of 0.39, a quick ratio of 4.87 and a current ratio of 4.87.</p>
<div class="lb-trans"><p>该公司的市值为 43.1 亿美元，市盈率为-24.33，贝塔值为 1.00。该公司的 50 日移动平均价格为 20.67 美元，200 日移动平均价格为 16.76 美元。该公司的债务与股本比率为 0.39，速动比率为 4.87，流动比率为 4.87。</p>
</div><p>Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The biotechnology company reported ($1.26) earnings per share for the quarter, missing the consensus estimate of ($0.94) by ($0.32). The firm had revenue of $27.77 million during the quarter, compared to the consensus estimate of $29.01 million. During the same quarter in the prior year, the company posted ($1.38) EPS. On average, research analysts expect that Arrowhead Pharmaceuticals, Inc. will post -2.42 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>箭头制药（NASDAQ:ARWR - 获取免费报告）最近于 8 月 7 日发布了季度财报。该生物技术公司报告本季度每股收益为（1.26 美元），低于市场共识预期的（0.94 美元）32 美分。该公司在本季度的收入为 2777 万美元，而市场共识预期为 2901 万美元。在去年同期，该公司每股收益为（1.38 美元）。研究分析师平均预计箭头制药公司在本财年将发布每股收益为-2.42 美元。</p>
</div><h2>Insider Activity at Arrowhead Pharmaceuticals</h2>
<div class="lb-trans"><h2>箭头制药的内部活动</h2>
</div><p>In other news, insider James C. Hamilton sold 15,000 shares of the business's stock in a transaction that occurred on Friday, September 12th. The stock was sold at an average price of $30.00, for a total value of $450,000.00. Following the transaction, the insider directly owned 232,122 shares of the company's stock, valued at $6,963,660. The trade was a 6.07% decrease in their position. The sale was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is available through the SEC website. Over the last 90 days, insiders sold 40,000 shares of company stock valued at $1,025,000. 4.30% of the stock is owned by insiders.</p>
<div class="lb-trans"><p>在其他消息中，内部人士詹姆斯·C·汉密尔顿在 9 月 12 日的交易中出售了 15,000 股公司的股票。该股票以平均价格 30.00 美元出售，总价值为 450,000.00 美元。交易后，内部人士直接持有 232,122 股公司的股票，价值 6,963,660 美元。此次交易使其持股减少了 6.07%。该出售在与证券交易委员会的法律文件中披露，相关信息可通过 SEC 网站获取。在过去 90 天内，内部人士出售了价值 1,025,000 美元的 40,000 股公司股票。4.30% 的股票由内部人士持有。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>Several institutional investors and hedge funds have recently modified their holdings of the business. Exchange Traded Concepts LLC lifted its holdings in Arrowhead Pharmaceuticals by 31.8% during the 1st quarter. Exchange Traded Concepts LLC now owns 49,247 shares of the biotechnology company's stock worth $627,000 after buying an additional 11,879 shares in the last quarter. Hsbc Holdings PLC acquired a new position in Arrowhead Pharmaceuticals during the 1st quarter worth $173,000. GAMMA Investing LLC lifted its holdings in Arrowhead Pharmaceuticals by 297.6% during the 1st quarter. GAMMA Investing LLC now owns 2,175 shares of the biotechnology company's stock worth $28,000 after buying an additional 1,628 shares in the last quarter. New York State Teachers Retirement System lifted its holdings in Arrowhead Pharmaceuticals by 6.9% during the 1st quarter. New York State Teachers Retirement System now owns 148,376 shares of the biotechnology company's stock worth $1,890,000 after buying an additional 9,593 shares in the last quarter. Finally, Principal Financial Group Inc. lifted its holdings in Arrowhead Pharmaceuticals by 117.8% during the 1st quarter. Principal Financial Group Inc. now owns 629,075 shares of the biotechnology company's stock worth $8,014,000 after buying an additional 340,191 shares in the last quarter. 62.61% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>几家机构投资者和对冲基金最近调整了对该公司的持股。交易所交易概念公司在第一季度将其在箭头制药的持股增加了 31.8%。交易所交易概念公司目前持有 49,247 股生物技术公司的股票，价值 627,000 美元，此前在上个季度购买了 11,879 股。汇丰控股在第一季度获得了箭头制药的新头寸，价值 173,000 美元。GAMMA 投资公司在第一季度将其在箭头制药的持股增加了 297.6%。GAMMA 投资公司目前持有 2,175 股生物技术公司的股票，价值 28,000 美元，此前在上个季度购买了 1,628 股。纽约州教师退休系统在第一季度将其在箭头制药的持股增加了 6.9%。纽约州教师退休系统目前持有 148,376 股生物技术公司的股票，价值 1,890,000 美元，此前在上个季度购买了 9,593 股。最后，Principal Financial Group Inc.在第一季度将其在箭头制药的持股增加了 117.8%。Principal Financial Group Inc.目前持有 629,075 股生物技术公司的股票，价值 8,014,000 美元，此前在上个季度购买了 340,191 股。62.61% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>Arrowhead Pharmaceuticals Company Profile</h2>
<div class="lb-trans"><h2>箭头制药公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.</p>
<div class="lb-trans"><p>箭头制药公司在美国开发用于治疗难治性疾病的药物。该公司的产品管线包括 Plozasiran，目前处于 2b 期和一项 3 期临床试验中，用于治疗高甘油三酯血症、混合性血脂异常和乳糜微粒血症；Zodasiran 目前处于 2b 期临床试验中，用于治疗血脂异常和高甘油三酯血症；ARO-PNPLA3，目前处于 1 期临床试验中，用于治疗非酒精性脂肪性肝炎患者；ARO-RAGE，目前处于 1/2a 期临床试验中，用于治疗炎症性肺部疾病；以及 ARO-MUC5AC，目前处于 1/2a 期临床试验中，用于治疗粘液阻塞性肺病。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than Arrowhead Pharmaceuticals</li>
<li>How to Choose Top Rated Stocks</li>
<li>The Fed Cut Rates: What Now for the S&amp;P 500 and Equity Markets?</li>
<li>What is the S&amp;P 500 and How It is Distinct from Other Indexes</li>
<li>Bloom Energy Booms on AI Power Demand and Analyst Upgrades</li>
<li>Growth Investing: Should You Adopt This Investing Strategy in 2022?</li>
<li>New Catalysts Build Positive Pressure on Intel Stock</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比箭头制药更好</li>
<li>如何选择顶级评级股票</li>
<li>美联储降息：现在 S&amp;P 500 和股市该怎么办？</li>
<li>什么是 S&amp;P 500，它与其他指数有何不同</li>
<li>Bloom Energy 因 AI 电力需求和分析师升级而蓬勃发展</li>
<li>增长投资：您应该在 2022 年采用这种投资策略吗？</li>
<li>新催化剂为英特尔股票带来积极压力</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将有关此故事的任何问题或意见发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Arrowhead Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在箭头制药吗？</h2>
</div><p>Before you consider Arrowhead Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑箭头制药之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Arrowhead Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前立即购买……而箭头制药并不在名单上。</p>
</div><p>While Arrowhead Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然箭头制药目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

箭头制药（NASDAQ:ARWR）创下一年新高 - 事情经过